These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 7483646

  • 21. Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo.
    Tulunay FC, Karan O, Aydin N, Culcuoglu A, Guvener A.
    Cephalalgia; 1987 Jun; 7(2):131-3. PubMed ID: 3301001
    [Abstract] [Full Text] [Related]

  • 22. Repetitive dihydroergotamine nasal spray for treatment of refractory headaches: an open-label pilot study.
    Weintraub J.
    Curr Med Res Opin; 2006 Oct; 22(10):2031-6. PubMed ID: 17022862
    [Abstract] [Full Text] [Related]

  • 23. Dihydroergotamine: role in the treatment of migraine.
    Schürks M.
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1141-8. PubMed ID: 19624283
    [Abstract] [Full Text] [Related]

  • 24. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine.
    Saper JR, Silberstein S.
    Headache; 2006 Nov; 46 Suppl 4():S171-81. PubMed ID: 17078849
    [Abstract] [Full Text] [Related]

  • 25. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
    Tas C, Joyce JC, Nguyen HX, Eangoor P, Knaack JS, Banga AK, Prausnitz MR.
    J Control Release; 2017 Dec 28; 268():159-165. PubMed ID: 29051065
    [Abstract] [Full Text] [Related]

  • 26. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.
    Silberstein S.
    Expert Opin Pharmacother; 2012 Sep 28; 13(13):1961-8. PubMed ID: 22860628
    [Abstract] [Full Text] [Related]

  • 27. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler.
    Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan NM.
    Headache; 2008 Mar 28; 48(3):355-67. PubMed ID: 18179563
    [Abstract] [Full Text] [Related]

  • 28. [Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo].
    Hoernecke R, Doenicke A.
    Med Klin (Munich); 1993 Nov 15; 88(11):642-8. PubMed ID: 8295604
    [Abstract] [Full Text] [Related]

  • 29. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group.
    Gallagher RM.
    Arch Neurol; 1996 Dec 15; 53(12):1285-91. PubMed ID: 8970458
    [Abstract] [Full Text] [Related]

  • 30. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial.
    Dowson AJ, Charlesworth BR, Green J, Färkkilä M, Diener HC, Hansen SB, Gawel M, INDEX Study Group.
    Headache; 2005 Jan 15; 45(1):17-24. PubMed ID: 15663608
    [Abstract] [Full Text] [Related]

  • 31. Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment.
    Dahlöf C, Maassen Van Den Brink A.
    Headache; 2012 Apr 15; 52(4):707-14. PubMed ID: 22444161
    [Abstract] [Full Text] [Related]

  • 32. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.
    Silberstein SD, Young WB, Hopkins MM, Gebeline-Myers C, Bradley KC.
    Headache; 2007 Jun 15; 47(6):878-85. PubMed ID: 17578539
    [Abstract] [Full Text] [Related]

  • 33. [Pharmacologic treatment of acute migraine attack in children].
    Cuvellier JC, Joriot S, Auvin S, Vallée L.
    Arch Pediatr; 2005 Mar 15; 12(3):316-25. PubMed ID: 15734131
    [Abstract] [Full Text] [Related]

  • 34. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.
    Silberstein SD, Kori SH.
    CNS Drugs; 2013 May 15; 27(5):385-94. PubMed ID: 23620146
    [Abstract] [Full Text] [Related]

  • 35. Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review.
    Tfelt-Hansen PC.
    Cephalalgia; 2013 Oct 15; 33(13):1122-31. PubMed ID: 23588793
    [Abstract] [Full Text] [Related]

  • 36. Intravenous dihydroergotamine therapy for pediatric abdominal migraines.
    Raina M, Chelimsky G, Chelimsky T.
    Clin Pediatr (Phila); 2013 Oct 15; 52(10):918-21. PubMed ID: 23820001
    [Abstract] [Full Text] [Related]

  • 37. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
    Winner P, Rothner AD, Wooten JD, Webster C, Ames M.
    Headache; 2006 Feb 15; 46(2):212-22. PubMed ID: 16492230
    [Abstract] [Full Text] [Related]

  • 38. Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine.
    Dafer RM, Tietjen GE, Rothrock JF, Vann RE, Shrewsbury SB, Aurora SK.
    Headache; 2024 Sep 15; 64(8):983-994. PubMed ID: 38800847
    [Abstract] [Full Text] [Related]

  • 39. [Treatment of transformed refractory migraine with intravenous dihydroergotamine].
    Cid C, Ortega-Valín F, Valero M, Muñoz R, Pascual J.
    Neurologia; 1999 Sep 15; 14(6):315-8. PubMed ID: 10439626
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.